Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COL1A1 | P02452 | 11/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Matrinic Acid SCHEMBL15134531 | 1.00 | COL1A1 (0.35) | COL1A1ITGB3ITGA2BCYP1A2MAPK1 | |
| SCHEMBL24322596 | 0.75 | CHRM2 (0.35) | — | |
| SCHEMBL24322599 | 0.73 | CHRM2 (0.35) | SMN1; SMN2 | |
| SCHEMBL14865287 | 0.71 | COL1A1 (0.53) | COL1A1 | |
| SCHEMBL16279037 | 0.66 | SLC6A1 (0.36) | CYP1A2 | |
| SCHEMBL9391353 | 0.61 | CYP1A2 (0.40) | ITGB3ITGA2BCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL3102769 | 0.60 | — | — | |
| SCHEMBL22267901 | 0.58 | CYP1A2 (0.44) | CYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL22618470 | 0.58 | PPARG (0.53) | — | |
| Adipic Acid SCHEMBL28454650 | 0.58 | LMNA (0.55) | CYP1A2MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130190345-A1 | MATRINIC ACID/MATRINE DERIVATIVES AND PREPARATION METHODS AND USES THEREOF | CSPC Zongqi Pharmaceutical Technology (Shijiahuang) Co., Ltd. (CN) | 2013-07-25 | — | — | US | disclosed |
| EP-2581376-A1 | MATRINIC ACID/ MATRINE DERIVATIVES AND PREPARATION METHODS AND USES THEREOF | Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (CN) | 2013-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190345-A1 | MATRINIC ACID/MATRINE DERIVATIVES AND PREPARATION METHODS AND USES THEREOF | MATR3, MMP7, MAT1A | COL1A1 87/4885ITGB3 1582/4885ITGA2B 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.